BPC-157 for Joint Pain: What the New 2026 Research Really Says
A new paper in a major orthopaedic journal reports that over 90 percent of patients saw symptom reduction after BPC-157 injections for joint injuries. But this peptide sits in a regulatory grey zone in the UK — and that matters before you consider spending a penny on it. Here is what the research actually shows.